Navigation Links
Labopharm files New Drug Submission with Health Canada for novel antidepressant
Date:8/5/2009

LAVAL, QC, Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada for its novel formulation of the antidepressant trazodone.

"We are pleased to file our New Drug Submission to Health Canada," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We believe the $800 million-plus Canadian market for antidepressants represents a significant opportunity for our trazodone formulation and we are currently in discussions with potential partners to support the commercialization of our product in Canada."

Labopharm's NDS is based on data from five pivotal pharmacokinetic studies and the positive results from a North American Phase III placebo controlled clinical trial (study 04ACL3-001), which enrolled more than 400 patients.

The eight-week randomized, double-blind, two-arm, multi-centre Phase III study in patients with major unipolar depressive disorder demonstrated the efficacy of Labopharm's formulation as a treatment for depression, as well as its positive effect on quality of sleep. The primary efficacy endpoint of the study was to compare the change in the Hamilton Rating Scale for Depression (HAMD-17) total score from baseline to the end of the study in the trazodone group versus the placebo group. Statistical significance was achieved for the primary endpoint (p value of 0.012). The majority of the secondary efficacy end points, including the HAMD-17 depressed mood item, the Clinical Global Impressions Severity (CGI-S) scale, the Montgomery Asberg Depression Rating Scale (MADRS) total score and a Responder's Analysis showed statistical significance in favor of the group administered Labopharm's trazodone. In addition, patients on Labopharm's trazodone demonstrated significant improve
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... 2014 New ... the Philadelphia Area ... biotechnology company focused on developing pleuromutilins, a new ... caused by resistant gram-positive and gram-negative pathogens, today ... Schmid will remain a member of the ...
(Date:9/3/2014)... ,    ... ~   Kiadis Pharma B.V. ... biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, ... , MD PhD, as its Chief Medical Officer. ... at Ceronco Biosciences. Prior to that he was VP ...
(Date:9/3/2014)... BUDAPEST, Hungary , Sept. 3, 2014 ... hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") ... and license agreement to co-develop and commercialize bremelanotide ... European Union, other European countries and additional selected ... with a strong focus in female health and ...
Breaking Medicine Technology:Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 2Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 3Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 2Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 3Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 4Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 5
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
(Date:9/3/2014)... Seattle, Wa (PRWEB) September 03, 2014 ... And Body,” a new report created by Tiffany Chou ... for dealing with skin problems including wrinkles and ... report, people will discover some common causes of wrinkles ... repeated facial expressions ,     Sun exposure: excessive exposure ...
(Date:9/3/2014)... Washington has many auto accidents every ... and have severe consequences as they impact the lives ... discusses how they handle these difficult cases . ... Firm, has worked with trucking accident litigation cases for ... usually backed by multiple lawyers and lots of money, ...
(Date:9/3/2014)... 03, 2014 In light of the ... Flood Law Group , a nationally esteemed personal injury ... the latest information is extremely important. The firm ... spreading awareness by sponsoring a website, designed as a ... their legal right to financial compensation. , Among those ...
(Date:9/3/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Pedigree nutrition for dogs . , Mars ... Pedigree Adult Complete Nutrition dry dog food products are ... material. The reason for the recall is that the product ... packages during the production process. These fragments may present a ...
(Date:9/3/2014)... Columbus, OH (PRWEB) September 03, 2014 ... in quality living options and innovative services for older ... Sarah Moore Health Care Center , (Sarah Moore ... 20 years of experience in the health care industry, ... facilities in Ohio including the MacIntosh Company and HCR ...
Breaking Medicine News(10 mins):Health News:“Home Remedies For Wrinkles And Age Spots On Face And Body,” A New Report On Vkool.com, Reveals Natural And Effective Methods For Dealing With Skin Problems 2Health News:Trucking Litigation Cases are Discussed in Recent Article from The Jones Firm 2Health News:Flood Law Group Spreads Awareness in Wake of Most Recent GM Recall Announcement 2Health News:Pedigree Adult Complete Nutrition for Dogs Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Arnett to Lead Delaware’s Sarah Moore Health Care Center 2
... According to it, the packaging or covering on the ... they claim to be able to cure. ... area of licensed medicines, the National Rules System was ... no scientific proof to confirm their claims will be ...
... study by the UC Davis researchers states that children from ... choosing better after school snacks. // ,The study by ... September issue of the American Journal of Public Health, has ... the vending machines aren't the only places that need to ...
... an increased risk of developing lymphoma and leukemia. The ... pain does have the risk of cancer. //Researchers speculate ... alpha (TNFá) antagonists, a type of biologic DMARD may ... which work by attaching to and impeding chemical messengers ...
... and vegetable juices may have the unique property or reducing the ... examined more than 2,000 people in the study, which appears in ... ,The researchers found that the risk of Alzheimer's was reduced by ... least three times a week as compared to those who drank ...
... past decade saw a decrease in traumatic head injuries ... according to a new report released on Wednesday.// ... hospital admissions for traumatic head injuries from 1994 to ... 35 per cent since 1994, with children and youth ...
... Research Institute are optimistic about a visual device that may ... , ,During a study to gauge the ... was a marked increase in the way the visually impaired ... which comprises of a small camera, pocket-sized computer and see-through ...
Cached Medicine News:Health News:Doctors worried about Homeopathic licensing 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 3Health News:RA Drugs Not Implicated In Cancer 2
... synergy T-EP Developed in collaboration with ... and an exceptionally high standard of ... Multimedia technology and design expertise to ... 2, 5 or 10-channel Medelec Synergy ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... of the MYOHANDY family are probably ... MYOQUICK - SystemPLUS line. Based on ... systems of the ISA 100x EP ... ISA 1002 EP) , 4 channels ...
Medicine Products: